Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02471716 · ClinicalTrials.gov registry record · Phase 1
Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor
A Phase 1 study of Tenosynovial Giant Cell Tumor and Pigmented Villonodular Synovitis, sponsored by Five Prime Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
- 12
- Study locations
NCT02471716: Completed Phase 1 study of Tenosynovial Giant Cell Tumor and Pigmented Villonodular Synovitis, sponsored by Five Prime Therapeutics.
NCT02471716 is a Phase 1 study of Tenosynovial Giant Cell Tumor and Pigmented Villonodular Synovitis that has completed, run by Five Prime Therapeutics. The registered enrollment target is 66 participants, below the 110-participant average among 8 other Tenosynovial Giant Cell Tumor trials with a reported enrollment target (40% lower). The trial reports 12 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02471716, a Phase 1 study of Tenosynovial Giant Cell Tumor and Pigmented Villonodular Synovitis, has completed, sponsored by Five Prime Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is a phase 1/2 single arm, open-label, safety, tolerability, and PK study of cabiralizumab in PVNS/dt-TGCT patients.
Primary Outcome
Number of participants with grade 3 and grade 4 adverse events (AE) defined as dose limiting toxicities (DLTs) in Phase 1
Conditions Studied
Interventions
- BIOLOGICAL FPA008
Study Locations (12)
Other
- Institut Bergonie- CRLCC de Bordeaux et du Sud-Ouest - Bordeaux
- Centre Léon Bérard - Lyon
- Leiden University Medical Center - Leiden
- Klinika Nowotworow Tkanek Miekkich, Kosci i Czerniakow, Centrum Onkologii-Instytut im. M. Sklodowskiej-Curie - Warsaw
- University Hospitals Birmingham NHS Foundation Trust - Birmingham
- Oxford University Hospital NHS Trust - Oxford
California
- Cedars-Sinai Medical Center - Los Angeles
- Sarcoma Oncology Research Center LLC - Santa Monica
- Stanford Medicine - Stanford
Massachusetts
- Dana-Farber Cancer Institute - Boston
Texas
- The University of Texas, MD Anderson Cancer Center - Houston
Jongno-gu
- Seoul National University Hospital - Seoul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2015-06 |
| Est. Completion | 2020-04-30 |
| Phase | Phase 1 |
What the finished NCT02471716 record still lists
NCT02471716 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 110-participant average among 8 other Tenosynovial Giant Cell Tumor trials with a reported enrollment target (40% lower).
The record links to 2 conditions, with Tenosynovial Giant Cell Tumor appearing as the primary indexed condition, and to 1 intervention - of which FPA008 is the first listed.
NCT02471716 lists 12 locations in 5 states (Other, California, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT02471716 about?
NCT02471716 is a clinical study titled "Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor". This is a phase 1/2 single arm, open-label, safety, tolerability, and PK study of cabiralizumab in PVNS/dt-TGCT patients.
What is the current status of trial NCT02471716?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2015-06. Estimated completion is 2020-04-30.
What conditions does trial NCT02471716 study?
This clinical trial studies the following conditions: Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis.
What interventions are being tested in trial NCT02471716?
The interventions under investigation include: FPA008 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02471716?
This trial is sponsored by Five Prime Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02471716 being conducted?
This trial has 12 study locations across California, Massachusetts, Texas, Jongno-gu. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tenosynovial Giant Cell Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02471716's enrollment target sits among peer trials
66 7th of 8 higher than 2 of 8 other Tenosynovial Giant Cell Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tenosynovial Giant Cell Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
RECRUITING · Phase 1
-
Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
ACTIVE NOT RECRUITING · Phase 1
-
Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib
RECRUITING
-
A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment
RECRUITING
-
Study of Vimseltinib for Tenosynovial Giant Cell Tumor
ACTIVE NOT RECRUITING · Phase 3
-
Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia